Premium
Losigamone add‐on therapy in partial epilepsy: a placebo‐controlled study
Author(s) -
Bauer J.,
Dienel A.,
Elger C. E.
Publication year - 2001
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2001.d01-25.x
Subject(s) - placebo , tolerability , medicine , anticonvulsant , partial epilepsy , adverse effect , partial seizures , epilepsy , anesthesia , psychiatry , alternative medicine , pathology
Objectives– To evaluate the efficacy and tolerability of losigamone (LSG). Patients and methods – Double‐blind, placebo‐controlled add‐on study with 3×500 mg LSG/die for the treatment of chronic partial seizures in 203 patients (99 treated with LSG, 104 on placebo). Results – The median percent change of seizures was 14.9% (LSG) versus 6.7% (placebo) ( P =0.004). Seizure frequency was decreased by more than 50% in 22.3% (LSG) and 14.6% (placebo) of patients ( P =0.13). Mean percent change of seizures was best in patients with only one additional anticonvulsant drug (LSG versus placebo, P =0.004). Adverse events (usually CNS‐related side effects of mild to moderate intensity) were reported in 59.6% (LSG) and 37.5% (placebo) of patients. Conclusions – LSG proved to be an effective and well tolerated anticonvulsant drug for the treatment of chronic partial seizures.